journal article·2019-10-30

Improved Label-Free Identification of Individual Exosome-like Vesicles with Au@Ag Nanoparticles as SERS Substrate

Juan C. Fraire, Stephan Stremersch, Davinia Bouckaert, Tinne Monteyne, Thomas De Beer, Pieter Wuytens, Riet De Rycke, Andre G. Skirtach, Koen Raemdonck, Stefaan De Smedt, Kevin Braeckmans

ACS Applied Materials & Interfaces· Volume 11· Issue 43
Publisher page

Abstract

Exosome-like vesicles (ELVs) are nanovectors released by cells that are endowed with a variety of molecules, including proteins, nucleic acids, and chemicals that reflect the molecular signature of the producing cell. Given their presence in many biofluids, they form an easily accessible biomarker for early disease detection. Previously we demonstrated the possibility of identifying individual ELVs by analyzing their molecular signatures with surface-enhanced Raman scattering (SERS) after functionalization of ELVs with 4-(dimethylamino)pyridine (DMAP)-stabilized gold nanoparticles (AuNP). Although this strategy was capable of distinguishing ELVs from different cellular origins, the quality of the SERS spectra was suboptimal due to high background coming from the DMAP stabilizing molecules at the AuNP surface. In this study we demonstrate that it is possible to eliminate interfering SERS signals from stabilizing molecules at the AuNP surface by overgrowing in situ the ELV-attached AuNPs with a silver layer so as to form a core–shell nanoparticle (Au@AgNPs) directly at the ELV surface. As such it represents the first known strategy to generate clear SERS spectral fingerprints of delicate biological structures without interference of linker molecules that are needed to ensure colloidal stability of the plasmonic NP and to allow them to associate to the ELV surface. This new strategy using core–shell plasmonic NPs as SERS substrate showed higher near-field enhancements than previous approaches, which resulted in SERS spectra with improved signal-to-noise ratio. This allowed us to discriminate individual vesicles derived from B16F10 melanoma cells and red blood cells (RBC) with an unprecedented sensitivity and specificity >90%. Importantly, thanks to the higher near field enhancement the acquisition time could be reduced by 20-fold in comparison to previously reported strategies, paving the way toward high-throughput label-free single ELV identification.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Gold and Silver Nanoparticles Synthesis and Applications · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (44)

Show source-provided references
1. 10.1083/jcb.20121113810.1083/jcb.201211138 ↗
2. 10.1038/ncb180010.1038/ncb1800 ↗
3. 10.1126/science.aaa402410.1126/science.aaa4024 ↗
4. 10.1016/j.canlet.2014.10.02710.1016/j.canlet.2014.10.027 ↗
5. 10.1021/acs.nanolett.8b0118410.1021/acs.nanolett.8b01184 ↗
6. 10.1021/acsanm.8b0026710.1021/acsanm.8b00267 ↗
7. Wang, W.; Luo, J.; Wang, S. Recent Progress in Isolation and Detection of Extracellular Vesicles for Cancer Diagnostics, 2018; 1800484, 1–27.10.1002/adhm.201800484 ↗
8. 10.1186/s40169-017-0178-x10.1186/s40169-017-0178-x ↗
9. Wu, A. Y.; Ueda, K.; Lai, C. P. Proteomic Analysis of Extracellular Vesicles for Cancer Diagnostics, 2019; 1800162, 1–12.10.1002/pmic.201800162 ↗
10. Yamashita T. · Pharmazie · 2013 · 68 · 969
11. 10.1038/nbt.288610.1038/nbt.2886 ↗
12. 10.1021/acs.analchem.7b0091110.1021/acs.analchem.7b00911 ↗
13. 10.1002/smll.20160039310.1002/smll.201600393 ↗
14. 10.1039/C8AN01041B10.1039/C8AN01041B ↗
15. 10.1021/jp312370910.1021/jp3123709 ↗
16. Fraire J. C. · 2016 · 13110.1016/B978-0-323-41736-5.00005-4 ↗
17. 10.1146/annurev-physchem-032511-14375710.1146/annurev-physchem-032511-143757 ↗
18. 10.1021/acssensors.8b0104710.1021/acssensors.8b01047 ↗
19. 10.7150/thno.2135810.7150/thno.21358 ↗
20. 10.1016/j.mee.2012.03.02210.1016/j.mee.2012.03.022 ↗
21. 10.1039/C5NR01333J10.1039/C5NR01333J ↗
22. 10.3402/jev.v1i0.1917910.3402/jev.v1i0.19179 ↗
23. 10.1016/j.saa.2018.01.06310.1016/j.saa.2018.01.063 ↗
24. 10.1021/acs.chemrev.5b0026510.1021/acs.chemrev.5b00265 ↗
25. 10.1002/1521-3773(20010817)40:16<3001::AID-ANIE3001>3.0.CO;2-510.1002/1521-3773(20010817)40:16<3001::AID-ANIE3001>3.0.CO;2-5 ↗
26. 10.1021/la403707j10.1021/la403707j ↗
27. 10.2217/nnm.12.16310.2217/nnm.12.163 ↗
28. 10.1016/j.jconrel.2016.04.00510.1016/j.jconrel.2016.04.005 ↗
29. 10.1016/j.ijpharm.2017.10.02210.1016/j.ijpharm.2017.10.022 ↗
30. 10.1080/0570492070155153010.1080/05704920701551530 ↗
31. 10.1021/nl504444w10.1021/nl504444w ↗
32. 10.1016/j.bbamcr.2014.04.01210.1016/j.bbamcr.2014.04.012 ↗
33. Bohrem C. F. · 1983
34. 10.1103/PhysRevE.58.393110.1103/PhysRevE.58.3931 ↗
35. Palik E. · 1985
36. 10.1364/OE.20.02297610.1364/OE.20.022976 ↗
37. 10.1021/jp205158w10.1021/jp205158w ↗
38. Widayanti · J. Phys. Conf. Ser. · 2016 · 694 · 1
39. 10.1021/nn501575c10.1021/nn501575c ↗
40. 10.1021/nn300474p10.1021/nn300474p ↗
41. 10.1021/acs.jpcc.5b0164710.1021/acs.jpcc.5b01647 ↗
42. 10.1039/C6TC01499B10.1039/C6TC01499B ↗
43. 10.3390/app906113510.3390/app9061135 ↗
44. 10.1021/nl304703w10.1021/nl304703w ↗